KLK3 and posterior cortical atrophy: In a study published 2 years later [61], McKiernan et al. evaluate the clinical utility of ExoDx in comparison with standard clinical parameters for distinguishing grade (GG) ≥ 2 PCa from GG1 PCa and benign disease (in men eligible for the first biopsy) and conducted a prospective study of 503 patients aged ≥50 years with PSA “grey zone” (2–10 ng/mL).